cgs 25462 has been researched along with organophosphonates in 6 studies
| Studies (cgs 25462) | Trials (cgs 25462) | Recent Studies (post-2010) (cgs 25462) | Studies (organophosphonates) | Trials (organophosphonates) | Recent Studies (post-2010) (organophosphonates) |
|---|---|---|---|---|---|
| 7 | 0 | 0 | 9,968 | 880 | 3,596 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berry, C; Blanchard, L; De Lombaert, S; el-Chehabi, L; Erion, MD; Ghai, RD; Sakane, Y; Tan, J; Trapani, AJ | 1 |
| De Lombaert, S; Erion, MD; Ghai, RD; Lappe, RW; Peppard, JV; Trapani, AJ; Worcel, M | 1 |
| Cipriano, A; Maniara, WM; Powell, ML | 1 |
| Pu, Q; Schiffrin, EL; Touyz, RM | 1 |
| Perlini, S | 1 |
| Amiri, F; Gannon, P; Pu, Q; Schiffrin, EL | 1 |
6 other study(ies) available for cgs 25462 and organophosphonates
| Article | Year |
|---|---|
N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors.
Topics: Animals; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Half-Life; Neprilysin; Organophosphonates; Phenylalanine; Phosphopeptides; Prodrugs; Rats; Structure-Activity Relationship | 1994 |
The pharmacology of CGS 25462: a potent, orally bioavailable, long-acting inhibitor of neutral endopeptidase 24.11.
Topics: Administration, Oral; Amino Acid Sequence; Animals; Atrial Natriuretic Factor; Biological Availability; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Hypertension; Molecular Sequence Data; Neprilysin; Oligopeptides; Organophosphonates; Prodrugs; Rats; Substrate Specificity | 1993 |
Quantitative analytical methods for the determination of a new hypertension drug, CGS 25462, and its metabolites (CGS 25659 and CGS 24592) in human plasma by high-performance liquid chromatography.
Topics: Administration, Oral; Antihypertensive Agents; Biphenyl Compounds; Chromatography, High Pressure Liquid; Circadian Rhythm; Half-Life; Humans; Male; Organophosphonates; Phenylalanine; Prodrugs; Protease Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Temperature; Time Factors | 1998 |
Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Collagen; Desoxycorticosterone; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; Hypertension; Male; Mesenteric Arteries; Myocardium; Neprilysin; Organ Size; Organophosphonates; Pyridines; Rats; Rats, Sprague-Dawley; Sodium Chloride; Systole; Thiazepines; Vascular Resistance | 2002 |
The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cell Adhesion Molecules; Desoxycorticosterone; Drug Therapy, Combination; Fibrosis; Heart Diseases; Hypertension; Inflammation; Kidney Diseases; Metalloendopeptidases; Neprilysin; Organophosphonates; Pyridines; Rats; Thiazepines | 2005 |
Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Pressure; Cell Adhesion Molecules; Collagen; Desoxycorticosterone; Drug Therapy, Combination; Enalapril; Fibrosis; Heart Diseases; Hypertension; Inflammation; Kidney Diseases; Metalloendopeptidases; Neprilysin; NF-kappa B; Organophosphonates; Pyridines; Rats; Rats, Sprague-Dawley; Thiazepines | 2005 |